Medicine
Raxibacumab 1700 mg/34 mL injection
Raxibacumab 1700 mg/34 mL injection is a generic prescription medicine for intravenous use, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store vial in original carton until time of use.
Key facts
- Active ingredient (INN)
- Raxibacumab
- Brand
- Sold under the generic name
- Strength
- 1700 mg/34 mL
- Dosage form
- Injection
- Route
- Intravenous
- Packs
- 1 vial of 34 mL
- Manufacturer
- Emergent BioDefense Operations Lansing
- Origin register
- US FDA, United States
- Storage
- Store vial in original carton until time of use.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- J06BB18 Raxibacumab
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 14 December 2012
- Identifiers
- RxCUI 1366571DailyMed set ID f6927e91-bb46-47b3-ab66-f9d8a9d7b12aNDC 71655-103Application BLA125349
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial, single-use in 1 carton / 34 mL in 1 vial, single-use | 71655-103-01 | Emergent BioDefense Operations Lansing | 14 December 2012 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 14 December 2012 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Raxibacumab is an anthrax protective antigen-directed antibody indicated for the treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis, among other approved uses. It is available as injection for intravenous use. MedsAcross supplies Raxibacumab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about RaxibacumabFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Raxibacumab prescribing information (Emergent BioDefense Operations Lansing) · U.S. National Library of Medicine, DailyMed
Need Raxibacumab 1700 mg/34 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.